224 related articles for article (PubMed ID: 25318182)
1. [Anti-VEGF therapy to treat diabetic macular edema].
Takamura Y
Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
[No Abstract] [Full Text] [Related]
2. Diabetic macular edema.
Lang GE
Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
O'Malley PG
Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
[No Abstract] [Full Text] [Related]
4. Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion.
Huang P; Song Z; Sun X
Chin Med J (Engl); 2014; 127(16):3019-23. PubMed ID: 25131244
[No Abstract] [Full Text] [Related]
5. Evidence for anti-VEGF treatment of diabetic macular edema.
Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
[TBL] [Abstract][Full Text] [Related]
6. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
Ollendorf DA; Colby JA; Pearson SD
Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
[TBL] [Abstract][Full Text] [Related]
8. [Molecular targeting therapy for diabetic retinopathy].
Nakao S; Yoshida S; Enaida H; Ishibashi T
Nihon Rinsho; 2012 Nov; 70 Suppl 8():628-46. PubMed ID: 23513915
[No Abstract] [Full Text] [Related]
9. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
Bandello F; Cicinelli MV; Parodi MB
Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF therapeutic approaches for diabetic macular edema.
Khurana RN; Do DV; Nguyen QD
Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
[No Abstract] [Full Text] [Related]
11. Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.
Prescrire Int; 2015 Sep; 24(163):207. PubMed ID: 26417628
[TBL] [Abstract][Full Text] [Related]
12. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
[No Abstract] [Full Text] [Related]
13. [From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
López-Gálvez MI; García-Campos JM
Arch Soc Esp Oftalmol; 2012 Dec; 87 Suppl 1():38-45. PubMed ID: 24278988
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
Stewart MW
Curr Diabetes Rev; 2012 Jul; 8(4):237-46. PubMed ID: 22515701
[TBL] [Abstract][Full Text] [Related]
17. Treatment choice for diabetic macular edema.
Martin DF; Maguire MG
N Engl J Med; 2015 Mar; 372(13):1260-1. PubMed ID: 25692914
[No Abstract] [Full Text] [Related]
18. Anti-VEGF for the management of diabetic macular edema.
Stefanini FR; Badaró E; Falabella P; Koss M; Farah ME; Maia M
J Immunol Res; 2014; 2014():632307. PubMed ID: 24741610
[TBL] [Abstract][Full Text] [Related]
19. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
Salam A; DaCosta J; Sivaprasad S
Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
